BRIEF-EMA Issues Advice On Use Of Lagevrio (Molnupiravir) For Treatment Of COVID-19

EMA: * EMA: EMA ISSUES ADVICE ON USE OF LAGEVRIO (MOLNUPIRAVIR) FOR THE TREATMENT OF COVID-19: 19/11/2021

* EMA: LAGEVRIO (MOLNUPIRAVIR) WHICH IS AVAILABLE AS CAPSULES, SHOULD BE TAKEN TWICE A DAY FOR 5 DAYS * EMA - LAGEVRIO CAN BE USED TO TREAT ADULTS WITH COVID-19 WHO DO NOT NEED SUPPLEMENTAL OXYGEN & WHO ARE AT INCREASED RISK OF DEVELOPING SEVERE COVID-19

* EMA SAYS ADVICE FOLLOWS A REVIEW OF DATA, INCLUDING DATA ON MEDICINE'S QUALITY AND RESULTS FROM COMPLETED AND ONGOING STUDIES * EMA: LAGEVRIO IS NOT RECOMMENDED DURING PREGNANCY AND IN WOMEN WHO CAN BECOME PREGNANT AND ARE NOT USING EFFECTIVE CONTRACEPTION

* EMA: WOMEN WHO CAN BECOME PREGNANT MUST USE EFFECTIVE CONTRACEPTION DURING TREATMENT AND FOR 4 DAYS AFTER THE LAST DOSE OF LAGEVRIO * EMA SAYS BREASTFEEDING SHOULD BE INTERRUPTED DURING TREATMENT WITH LAGEVRIO AND FOR 4 DAYS AFTER TREATMENT

* EMA SAYS ADVICE CAN NOW BE USED TO SUPPORT NATIONAL RECOMMENDATIONS ON POSSIBLE USE OF MEDICINE BEFORE MARKETING AUTHORISATION. * EMA SAYS LAGEVRIO SHOULD BE ADMINISTERED AS SOON AS POSSIBLE AFTER DIAGNOSIS OF COVID-19 AND WITHIN 5 DAYS OF START OF SYMPTOMS. Further company coverage:

(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)